PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congressional Research Service
Version 00 · Introduced in House · Feb 18, 2025
Lung Cancer Screening and Prevention Act of 2025
This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the Food and Drug Administration, regardless of whether they are recommended by the United States Preventive Services Task Force. The Centers for Medicare & Medicaid Services must set coverage and payment limits for such tests. (Currently, Medicare covers screening tests for the early detection of lung cancer if they are recommended by the task force.)
People & committees
Rep. Buchanan, Vern [R-FL-16] · R–FL
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Jun 11, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1406 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1406 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1406 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1406 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-02-18 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
This bill would let Medicare Part B cover additional lung cancer screening tests cleared or approved by the Food and Drug Administration. Coverage would be optional, with the Secretary deciding who qualifies, how often tests could be covered, and payment limits. These tests would go through Medicare’s nationwide coverage decision process, with one statutory determination requirement waived. The supplied text is a proposal, not evidence of enacted law.
the Secretary may provide for coverage under this part of other lung cancer screening tests that are cleared or approved by the Food and Drug Administration as preventive services when furnished to appropriate individuals (as determined by the Secretary), with such frequency and payment limits as the Secretary determines appropriate in consultation with appropriate organizations.
Coverage of other lung cancer screening tests under subparagraph (A) shall be determined using the process for making national coverage determinations (as defined in section 1869(f)(1)(B)), except that there shall be no requirement for a determination under section 1861(ddd)(3)(B) with respect to such test under such process.
apply with respect to coverage of preventive services under Part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.) on or after such date.
2025-02-18: Introduced in House
Section 1 would name the bill the Lung Cancer Screening and Prevention Act of 2025.
This Act may be cited as the Lung Cancer Screening and Prevention Act of 2025.
Section 2 would authorize coverage of additional screening tests alongside lung cancer screening already covered under Medicare national coverage determination 210.14. The additional tests must be cleared or approved by the Food and Drug Administration, but that status alone would not guarantee Medicare coverage.
in addition to preventive services consisting of screening tests for the early detection of lung cancer covered under this part pursuant to national coverage determination 210.14, the Secretary may provide for coverage under this part of other lung cancer screening tests that are cleared or approved by the Food and Drug Administration as preventive services
The Secretary would decide which individuals qualify for the additional tests and set testing-frequency and payment limits in consultation with appropriate organizations. The bill does not set those limits itself.
when furnished to appropriate individuals (as determined by the Secretary), with such frequency and payment limits as the Secretary determines appropriate in consultation with appropriate organizations.
Coverage decisions for the additional tests would have to use the national coverage determination process—Medicare’s process for nationwide coverage decisions. The bill would remove the requirement for a determination under section 1861(ddd)(3)(B) for these tests. The supplied text does not reproduce that requirement.
Coverage of other lung cancer screening tests under subparagraph (A) shall be determined using the process for making national coverage determinations (as defined in section 1869(f)(1)(B)), except that there shall be no requirement for a determination under section 1861(ddd)(3)(B) with respect to such test under such process.
The Secretary could still consider recommendations from preventive-services experts, including entities convened by the Secretary or the Director of the Agency for Healthcare Research and Quality. This provision would permit consideration of those recommendations without requiring it.
Nothing in clause (i) shall be construed as preventing the Secretary from considering recommendations made by entities with expertise in preventive services, including entities convened by the Secretary or the Director of the Agency for Healthcare Research and Quality, with respect to other lung cancer screening tests described in subparagraph (A).
If enacted, the amendments would take effect on the enactment date and apply to Medicare Part B preventive-service coverage on or after that date. This would make the authority effective; it would not itself require coverage of any particular additional test.
The amendments made by subsection (a) shall take effect on the date of the enactment of this Act, and apply with respect to coverage of preventive services under Part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.) on or after such date.
the Secretary may provide for coverage under this part of other lung cancer screening tests
The supplied actions snapshot, updated June 11, 2026, records introduction in the House on February 18, 2025, and referral that day to the Energy and Commerce and Ways and Means committees for provisions within their respective jurisdictions.
Source snapshot updated 2026-06-11T23:26:38Z.
2025-02-18: Introduced in House
2025-02-18: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A closer look
Reviewed version: Introduced in House · 2025-02-18. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced text. This conclusion does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for a particular recipient or place was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in accompanying materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
Findings to examine
The text contains a test-specific exception to a statutory coverage requirement within the bill’s main policy. This classification does not establish improper favoritism or a financial gain.
Other lung cancer screening tests cleared or approved by the Food and Drug Administration would receive a coverage pathway exempt from the determination requirement in section 1861(ddd)(3)(B). The exception is limited to this category of tests and supports the bill’s screening policy. Its practical significance is uncertain because the referenced requirement is not reproduced.
the Secretary may provide for coverage under this part of other lung cancer screening tests that are cleared or approved by the Food and Drug Administration as preventive services
Coverage of other lung cancer screening tests under subparagraph (A) shall be determined using the process for making national coverage determinations (as defined in section 1869(f)(1)(B)), except that there shall be no requirement for a determination under section 1861(ddd)(3)(B) with respect to such test under such process.
Full text preserved for this analysis. Legislative record snapshot: Jun 11, 2026. How PlainBill uses AI